Abstract #0200

Quantitative Transcatheter Intraarterial Perfusion MRI to Predict Drug Delivery during Chemoembolization for Hepatocellular Carcinoma

Dingxin Wang^1,2, Brian Jin³, Robert Lewandowski³, Robert Ryu³, Kent Sato³, Ann Ragin³, Laura Kulik⁴, Mary Mulcahy^5,6, Frank Miller³, Riad Salem^3,6, Andrew Larson^3,6, Reed Omary^3,6

¹Siemens Medical Solutions USA, Inc., Minneapolis, MN, USA; ²Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; ³Department of Radiology, Northwestern University, Chicago, IL, USA; ⁴Department of Hepatology, Northwestern University, Chicago, IL, USA; ⁵Department of Medicine, Northwestern University, Chicago, IL, USA; ⁶Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

This study accessed the utility of quantitative Transcatheter Intraarterial Perfusion (TRIP)-MRI for predicting chemotherapy-lipiodol delivery during transcatheter arterial chemoembolization (TACE). The volumes of drug distribution in the tumors and liver as well as the selectivity of chemotherapy emulsion delivery to the tumors obtained from pre-TACE TRIP-MRI highly correlated with corresponding parameters seen on CT scans after TACE. These findings suggest that quantitative TRIP-MRI may have the potential to provide important spatial biodistribution information of subsequent drug delivery during liver-directed transarterial locoregional therapies with same catheter positioning.